I agree that this site is using cookies. You can find further informations here.
X
G. Borthakur, Madan
125  results:
Search for persons X
?
1

FEMORAL GLAND SECRETION OF GEKKONIDS HEMIDACTYLUS AQUILONIU..:

Das, Madhurima ; G. Borthakur, Madan ; Roychoudhury, Shubhadeep..
Journal of microbiology, biotechnology and food sciences.  9 (2019)  1 - p. 156-159 , 2019
Link: https://doi.org/10.15414..
 
?
2

Microwave promoted one-pot synthesis of novel A-ring fused ..:

Borthakur, Moyurima ; Barthakur, Madan G. ; Boruah, Romesh C.
Steroids.  73 (2008)  5 - p. 539-542 , 2008
Link: https://doi.org/10.1016/..
 
?
3

Convenient preparation of A-ring fused pyridines from stero..:

Barthakur, Madan G. ; Borthakur, Moyurima ; Boruah, Romesh C.
Steroids.  73 (2008)  11 - p. 1137-1142 , 2008
Link: https://doi.org/10.1016/..
 
?
4

Conjugate base catalysed one-pot synthesis of pyrazoles fro..:

Saikia, Anil ; Barthakur, Madan G. ; Borthakur, Moyurima...
Tetrahedron Letters.  47 (2006)  1 - p. 43-46 , 2006
Link: https://doi.org/10.1016/..
 
?
5

P367: LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGE..:

Senapati, J. ; Jabbour, E. J. ; Short, N. J....
HemaSphere.  6 (2022)  - p. 267-268 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACI..:

Stein, E. ; de Botton, S. ; Pigneux, A....
HemaSphere.  6 (2022)  - p. 391-392 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE ..:

Bazinet, A. ; Kadia, T. ; Short, N....
HemaSphere.  6 (2022)  - p. 405-406 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNO..:

Haddad, F. ; Sasaki, K. ; Abuasab, T....
HemaSphere.  6 (2022)  - p. 440-441 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN..:

Senapati, J. ; Haddad, F. ; Ravandi, F....
HemaSphere.  6 (2022)  - p. 474-475 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLAS..:

Abuasab, T. ; Mohadam, S. F. ; Hwang, H....
HemaSphere.  6 (2022)  - p. 395-396 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY F..:

Venugopal, S. ; Jabbour, E. ; Pemmaraju, N....
HemaSphere.  6 (2022)  - p. 480-481 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN..:

Senapati, J. ; Kantarjian, H. ; Short, N....
HemaSphere.  6 (2022)  - p. 269-270 , 2022
Link: https://doi.org/10.1097/..
 
?
13

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBIN..:

Senapati, J. ; Ishizawa, J. ; Abbas, H. A....
HemaSphere.  6 (2022)  - p. 475-476 , 2022
Link: https://doi.org/10.1097/..
 
?
14

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITH..:

Short, N. ; Kantarjian, H. ; Ravandi, F....
HemaSphere.  6 (2022)  - p. 271-272 , 2022
Link: https://doi.org/10.1097/..
 
?
15

P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZ..:

Kadia, T. ; Ravandi, F. ; Borthakur, G....
HemaSphere.  6 (2022)  - p. 1080-1081 , 2022
Link: https://doi.org/10.1097/..
 
1-15